Literature DB >> 26415820

MicroRNA in prostate cancer.

Kasomva Khanmi1, Savarimuthu Ignacimuthu2, Michael Gabriel Paulraj1.   

Abstract

In the United States of America male prostate cancer (PCa) is the most dominant malignancy and the second highest cause of cancer-related mortality risk compared to lung and colon cancers. MicroRNAs (miRNAs) are a class of endogenously expressed small, non-coding, single-stranded RNA which function as regulators of gene expression. They influence various physiological and pathophysiological processes. In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androgen; MicroRNA (miRNA); Post-transcription; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26415820     DOI: 10.1016/j.cca.2015.09.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer.

Authors:  Yongyong Xi; Liang Wang; Chengcao Sun; Cuili Yang; Feng Zhang; Dejia Li
Journal:  Med Oncol       Date:  2016-10-12       Impact factor: 3.064

2.  A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.

Authors:  C Chang; J Liu; W He; M Qu; X Huang; Y Deng; L Shen; X Zhao; H Guo; J Jiang; X Y Fu; R Huang; D Zhang; J Yan
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

Review 3.  LncRNAs and miRNAs: potential biomarkers and therapeutic targets for prostate cancer.

Authors:  Guoxing Ma; Mingqing Tang; Yaqing Wu; Xiaoming Xu; Feng Pan; Ruian Xu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8.

Authors:  Ping Lin; Lijuan Zhu; Wenjing Sun; Zhengkai Yang; Hui Sun; Dong Li; Rongjun Cui; Xiulan Zheng; Xiaoguang Yu
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

5.  Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.

Authors:  A Valentino; A Calarco; A Di Salle; M Finicelli; S Crispi; R A Calogero; F Riccardo; A Sciarra; A Gentilucci; U Galderisi; S Margarucci; G Peluso
Journal:  Oncogene       Date:  2017-07-03       Impact factor: 9.867

6.  MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.

Authors:  H Q Mu; Y H He; S B Wang; S Yang; Y J Wang; C J Nan; Y F Bao; Q P Xie; Y H Chen
Journal:  Clin Transl Oncol       Date:  2019-10-30       Impact factor: 3.405

Review 7.  Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.

Authors:  Sijia Shen; Yuxin Lin; Xuye Yuan; Li Shen; Jiajia Chen; Luonan Chen; Lei Qin; Bairong Shen
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

8.  microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer.

Authors:  Dawei Wang; Guoliang Lu; Yuan Shao; Da Xu
Journal:  Biosci Rep       Date:  2017-03-15       Impact factor: 3.840

9.  The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms.

Authors:  Maria Yu Konoshenko; Evgeniy A Lekchnov; Olga E Bryzgunova; Ivan A Zaporozhchenko; Sergey V Yarmoschuk; Oksana A Pashkovskaya; Svetlana V Pak; Pavel P Laktionov
Journal:  Diagnostics (Basel)       Date:  2020-01-10

Review 10.  Targeting MicroRNAs in Prostate Cancer Radiotherapy.

Authors:  Jie Ni; Joseph Bucci; Lei Chang; David Malouf; Peter Graham; Yong Li
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.